Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization

J Infect Dis. 1995 Jul;172(1):217-9. doi: 10.1093/infdis/172.1.217.

Abstract

Four hundred nineteen children and adolescents immunized with live varicella vaccine 4-6 years earlier were enrolled in a study to evaluate the safety and immune response to a booster dose containing approximately 3300 pfu of virus. Of the subjects, 99% (414/419) maintained antibody to varicella zoster virus (VZV) with a geometric mean titer of 25.7 and mean stimulation index (SI) for VZV-specific lymphoproliferation response of 40.3 +/- 5.3 (SE). Some 7-10 days after the booster immunization, seropositivity rates increased to 100% (302/302), and GMT was 143.6 (anamnestic response). At 6 weeks after the booster inoculation, a subset of subjects had 100% seropositivity (74/74) with a GMT of 218.8 and an SI of 58.6. After 3 months, seropositivity was 100% (358/358), GMT was 119.0, and SI was 61.4.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibodies, Viral / blood
  • Antibody Formation
  • B-Lymphocytes / immunology*
  • Chickenpox Vaccine
  • Child
  • Child, Preschool
  • Female
  • Herpesvirus 3, Human / immunology*
  • Humans
  • Immunity, Cellular
  • Immunization, Secondary* / adverse effects
  • Infant
  • Male
  • Safety
  • T-Lymphocytes / immunology*
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / immunology*
  • Viral Vaccines / adverse effects
  • Viral Vaccines / immunology*

Substances

  • Antibodies, Viral
  • Chickenpox Vaccine
  • Vaccines, Attenuated
  • Viral Vaccines